| Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors AS Kanate, A Mussetti, MA Kharfan-Dabaja, KW Ahn, A DiGilio, ... Blood, The Journal of the American Society of Hematology 127 (7), 938-947, 2016 | 289 | 2016 |
| Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? U Bacher, E Klyuchnikov, J Le-Rademacher, J Carreras, P Armand, ... Blood, The Journal of the American Society of Hematology 120 (20), 4256-4262, 2012 | 151 | 2012 |
| Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous–allogeneic tandem transplantation in patients with … N Kröger, A Badbaran, T Zabelina, F Ayuk, C Wolschke, H Alchalby, ... Biology of Blood and Marrow Transplantation 19 (3), 398-404, 2013 | 118 | 2013 |
| Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma N Kröger, A Badbaran, M Lioznov, S Schwarz, S Zeschke, Y Hildebrand, ... Experimental hematology 37 (7), 791-798, 2009 | 106 | 2009 |
| JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation N Kröger, H Alchalby, E Klyuchnikov, A Badbaran, Y Hildebrandt, F Ayuk, ... Blood, The Journal of the American Society of Hematology 113 (8), 1866-1868, 2009 | 98 | 2009 |
| CD34+-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies E Klyuchnikov, J El-Cheikh, A Sputtek, M Lioznov, B Calmels, S Furst, ... Biology of blood and marrow transplantation 20 (3), 382-386, 2014 | 83 | 2014 |
| Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working … D McLornan, R Szydlo, L Koster, Y Chalandon, M Robin, C Wolschke, ... Biology of Blood and Marrow Transplantation 25 (11), 2167-2171, 2019 | 82 | 2019 |
| Reduced-intensity allografting as first transplantation approach in relapsed/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors E Klyuchnikov, U Bacher, NM Kröger, PN Hari, KW Ahn, J Carreras, ... Biology of Blood and Marrow Transplantation 21 (12), 2091-2099, 2015 | 61 | 2015 |
| Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients N Kröger, T Zabelina, E Klyuchnikov, M Kropff, KH Pflüger, A Burchert, ... Bone marrow transplantation 48 (3), 403-407, 2013 | 59 | 2013 |
| Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced‐intensity allografting E Klyuchnikov, E Holler, M Bornhäuser, G Kobbe, A Nagler, A Shimoni, ... British journal of haematology 159 (2), 172-181, 2012 | 59 | 2012 |
| Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant M Scordo, TP Wang, KW Ahn, Y Chen, S Ahmed, FT Awan, A Beitinjaneh, ... JAMA oncology 7 (7), 993-1003, 2021 | 52 | 2021 |
| Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML) E Klyuchnikov, N Kröger, TH Brummendorf, B Wiedemann, AR Zander, ... Biology of Blood and Marrow Transplantation 16 (3), 301-310, 2010 | 50 | 2010 |
| Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? E Klyuchnikov, U Bacher, T Kroll, TC Shea, HM Lazarus, C Bredeson, ... Bone marrow transplantation 49 (1), 1-7, 2014 | 49 | 2014 |
| Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma N Kröger, T Zabelina, J Berger, H Duske, E Klyuchnikov, T Binder, ... Leukemia 25 (10), 1657-1661, 2011 | 44 | 2011 |
| Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia B Wiedemann, E Klyuchnikov, N Kröger, T Zabelina, T Stahl, S Zeschke, ... Experimental hematology 38 (12), 1261-1271, 2010 | 43 | 2010 |
| Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or-mismatched sibling peripheral blood stem cell transplantation C Wolschke, T Zabelina, F Ayuk, H Alchalby, J Berger, E Klyuchnikov, ... Bone marrow transplantation 49 (1), 126-130, 2014 | 39 | 2014 |
| The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004 U Bacher, E Klyuchnikov, T Zabelina, H Ottinger, DW Beelen, ... Annals of hematology 88, 1237-1247, 2009 | 39 | 2009 |
| Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma E Klyuchnikov, U Bacher, K Woo Ahn, J Carreras, NM Kröger, PN Hari, ... Bone marrow transplantation 51 (1), 58-66, 2016 | 38 | 2016 |
| Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors A Oyekunle, E Klyuchnikov, S Ocheni, N Kröger, AR Zander, M Baccarani, ... Acta haematologica 126 (1), 30-39, 2011 | 34 | 2011 |
| Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia E Klyuchnikov, S Asenova, W Kern, G Kilinc, F Ayuk, B Wiedemann, ... Leukemia & lymphoma 51 (8), 1450-1463, 2010 | 34 | 2010 |
